Inhibition of the renin-angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia

International Journal of Cancer

Volumn 133, Issue 5, 2013, Pages 1234-1246

  Murphy, Kate T ^a   Chee, Annabel ^a   Trieu, Jennifer ^a   Naim, Timur ^a   Lynch, Gordon S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

angiotensin converting enzyme; atrophy; cancer cachexia; function; wasting

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; PERINDOPRIL; PHOSPHATE BUFFERED SALINE; PROTEIN KINASE B; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CACHEXIA; CANCER INHIBITION; COLON TUMOR; CONTROLLED STUDY; DIAPHRAGM; DISEASE SEVERITY; DRUG EFFECT; ENZYME PHOSPHORYLATION; GRIP STRENGTH; LOCOMOTION; MALE; METABOLISM; MOUSE; MUSCLE FATIGUE; MUSCLE FUNCTION; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAROD TEST; SKELETAL MUSCLE; TIBIALIS ANTERIOR MUSCLE; WESTERN BLOTTING;

ANGIOTENSIN CONVERTING ENZYME; ATROPHY; CANCER CACHEXIA; FUNCTION; WASTING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CACHEXIA; CELL LINE, TUMOR; INTERLEUKIN-6; MALE; MICE; MOTOR ACTIVITY; MUSCLE FATIGUE; MUSCLE PROTEINS; MUSCLE, SKELETAL; NEOPLASMS; PERINDOPRIL; UBIQUITIN-PROTEIN LIGASES;

EID: 84879235354     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28128     Document Type: Article

References (49)

1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-95.
2. Bruera E,. ABC of palliative care. Anorexia, cachexia, and nutrition. Br Med J 1997; 315: 1219-22.
3. Murphy KT, Lynch GS,. Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2009; 14: 619-32.
4. Paul M, Poyan Mehr A, Kreutz R,. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
5. Jones A, Woods DR,. Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol 2003; 35: 855-66.
6. Danser AH, Koning MM, Admiraal PJ, et al. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol 1992; 263: H429-37.
7. Sanders PM, Russell ST, Tisdale MJ,. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005; 93: 425-34.
8. Russell ST, Sanders PM, Tisdale MJ,. Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett 2006; 231: 290-4.
9. Zhang L, Du J, Hu Z, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009; 20: 604-12.
10. Burniston JG, Saini A, Tan LB, et al. Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol 2005; 90: 755-61.
11. Wray DW, Nishiyama SK, Harris RA, et al. Angiotensin II in the elderly: impact of angiotensin II type 1 receptor sensitivity on peripheral hemodynamics. Hypertension 2008; 51: 1611-6.
12. Sun G, Haginoya K, Dai H, et al. Intramuscular renin-angiotensin system is activated in human muscular dystrophy. J Neurol Sci 2009; 280: 40-8.
13. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21: 53-7.
14. Graziani G, Badalamenti S, Del Bo A, et al. Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment. Kidney Int 1993; 44: 107-14.
15. Neo JH, Ager EI, Angus PW, et al. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 2010; 10: 134.
16. Kandpal N, Shukla GK, Bhatia N, et al. Oxidant, vitamin A and angiogenic markers in laryngeal cancer patients. J Laryngol Otol 2003; 117: 871-4.
17. Lieffers JR, Mourtzakis M, Hall KD, et al. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 2009; 89: 1173-9.
18. -/- mice enhances muscle function despite reducing muscle mass but compromises repair after injury. Am J Physiol 2012; 303: R321-31.
19. Bedair HS, Karthikeyan T, Quintero A, et al. Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. Am J Sports Med 2008; 36: 1548-54.
20. Burks TN, Andres-Mateos E, Marx R, et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011; 3: 82ra37.
21. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13: 204-10.
22. Smith N., Phase III study of Vitor in cancer cachexia after mixed results. APM Health Europe [internet] Available from:. http://www. apmhealtheurope.com/print-story.php?numero=L1135, Jan 16, 2006.
23. Schanze N, Springer J,. Evidence for an effect of ACE inhibitors on cancer cachexia. J Cachexia Sarcopenia Muscle 2012; 3: 139.
24. Murphy KT, Chee A, Trieu J, et al. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech 2012; 5: 533-45.
25. Campbell DJ, Kladis A, Duncan AM,. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-49.
26. Murphy KT, Chee A, Gleeson BG, et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol 2011; 301: R716-R26.
27. Herrera M, Sparks MA, Alfonso-Pecchio AR, et al. Lack of specificity of commercial antibodies leads to misidentification of Angiotensin type 1 receptor protein. Hypertension 2013; 61: 253-8.
28. Murphy KT, Ryall JG, Snell SM, et al. Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol 2010; 176: 2425-34.
29. Miyata S, Minobe W, Bristow MR, et al. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000; 86: 386-90.
30. Cosper PF, Leinwand LA,. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res 2011; 71: 1710-20.
31. Lambert F, Lecarpentier Y, Lompre AM, et al. Relations between myocardial contractility, myosin phenotype, and plasma angiotensin-converting enzyme activity in the cardiomyopathic hamster. J Cardiovasc Pharmacol 1995; 25: 410-5.
32. Guo CB, Zhang W, Ma DQ, et al. Hand grip strength: an indicator of nutritional state and the mix of postoperative complications in patients with oral and maxillofacial cancers. Br J Oral Maxillofac Surg 1996; 34: 325-7.
33. Fouladiun M, Korner U, Gunnebo L, et al. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res 2007; 13: 6379-85.
34. Tan BH, Fearon KC,. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11: 400-7.
35. Rezk BM, Yoshida T, Semprun-Prieto L, et al. Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS One 2012; 7: e30276.
36. Weber MA, Krakowski-Roosen H, Schroder L, et al. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol 2009; 48: 116-24.
37. Gorassini M, Bennett DJ, Kiehn O, et al. Activation patterns of hindlimb motor units in the awake rat and their relation to motoneuron intrinsic properties. J Neurophysiol 1999; 82: 709-17.
38. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5: 353-60.
39. Bish LT, Yarchoan M, Sleeper MM, et al. Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS One 2011; 6: e20856.
40. Tisdale MJ,. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000; 16: 1013-4.
41. Yoshikawa T, Noguchi Y, Doi C, et al. Insulin resistance was connected with the alterations of substrate utilization in patients with cancer. Cancer Lett 1999; 141: 93-8.
42. Henriksen EJ,. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol 2007; 293: R974-R80.
43. Neo JH, Malcontenti-Wilson C, Muralidharan V, et al. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007; 22: 577-84.
44. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-84.
45. Escobar E, Rodriguez-Reyna TS, Arrieta O, et al. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2: 385-99.
46. Ambrus JL, Ambrus CM, Mink IB, et al. Causes of death in cancer patients. J Med 1975; 6: 61-4.
47. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.
48. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-81.
49. Mooser V, Casley D, Trinder D, et al. Reduction in left ventricular mass in normotensive and spontaneously hypertensive rats given enalapril. Clin Exp Pharmacol Physiol 1991; 18: 341-4.